United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

Purpose: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL). Patients and Methods: Forty patients experiencing first (n = 21) or greater than or equal to second (n = 19) relapse were treated with daily infusions of ATO to a maximum of 60 doses or until all leukemic cells in bone marrow were eliminated. Patients who achieved a complete remission (CR) were offe red one consolidation course of ATO that began 3 to 4 weeks later. Patients who remained in CR were eligible to receive further cycles of ATO therapy on a maintenance study. Results: Thirty-four patients (85%) achieved a CR. Thirty-one patients (91% ) with CRs had posttreatment cytogenetic tests negative for t(15;17). Eight y-six percent of the patients who were assessable by reverse transcriptase polymerase chain reaction converted from positive to negative for the promy elocytic leukemia/retinoic acid receptor-alpha transcript by the completion of their consolidation therapy. Thirty-two patients received consolidation therapy, and 18 received additional ATO as maintenance. Eleven patients un derwent allogeneic (n = 8) or autologous (n = 3) transplant after ATO treat ment. The 18-month overall and relapse-free survival (RFS) estimates were 6 6% and 56%, respectively. Twenty patients (50%) had leukocytosis (> 10,000 WBC/muL) during induction therapy. Ten patients developed signs or symptoms suggestive of the APL syndrome and were effectively treated with dexametha sone. Electrocardiographic QT prolongation was common (63%). One patient ha d an absolute QT interval of > 500 msec and had an asymptomatic 7-beat run of torsades de pointe. Two patients died during induction, neither from dru g-related causes. Conclusion: This study establishes ATO as a highly effective therapy for pa tients with relapsed APL. J Clin Oncol 19:3852-3860. (C) 2001 by American S ociety of Clinical Oncology.